Can botox improve night‐time overactive bladder symptoms in women?

Despite the efficacy of intravesical onabotulinumtoxinA (Botox) therapy for urgency, urgency incontinence, and daytime frequency, its value in treatment of nocturia remains unclear. The aim of the prospective observational study was to assess the effect of onabotulinumtoxinA on night‐time symptoms in women with overactive bladder (OAB), including nocturia, night‐time urgency incontinence, and nocturnal voided volume as end‐points.

[1]  M. Miyazato,et al.  Effect of continuous positive airway pressure on nocturnal urine production in patients with obstructive sleep apnea syndrome , 2017, Neurourology and urodynamics.

[2]  Yuan-Hong Jiang,et al.  Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder , 2015, Neurourology and urodynamics.

[3]  Y. Izumiya,et al.  Nocturia in Patients With Sleep-Disordered Breathing and Cardiovascular Disease. , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[4]  D. Kwon,et al.  Effects of desmopressin for the treatment of nocturnal polyuria in elderly women: impact on related sleep quality. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[5]  Toshimitsu Kobayashi,et al.  Characterization of symptom bother and health‐related quality of life in Japanese female patients with overactive bladder , 2015, Neurourology and urodynamics.

[6]  P. Miotła,et al.  Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery , 2015, International Urogynecology Journal.

[7]  Kyu-Sung Lee,et al.  Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia , 2015, Neurourology and urodynamics.

[8]  Yuanshan Cui,et al.  The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta‐analysis , 2015, Neurourology and urodynamics.

[9]  M. Faraday,et al.  Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. , 2015, The Journal of urology.

[10]  B. Kollen,et al.  Impact of the International Continence Society (ICS) report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review , 2015, BJU international.

[11]  M. Drake.  Should nocturia not be called a lower urinary tract symptom? , 2015, European urology.

[12]  G. Guyatt,et al.  What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women , 2014, European urology.

[13]  C. Nardo,et al.  OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder , 2014, International journal of clinical practice.

[14]  K. Andersson,et al.  Terminology, epidemiology, etiology, and pathophysiology of nocturia , 2014, Neurourology and urodynamics.

[15]  P. Miotła,et al.  [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist]. , 2014, Ginekologia polska.

[16]  C. Nardo,et al.  OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. , 2013, European urology.

[17]  S. Madersbacher,et al.  Nocturnal polyuria: it's all about definition, and be Patient! , 2013, European urology.

[18]  T. Kessler,et al.  Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. , 2012, European urology.

[19]  P. Abete,et al.  Association between nocturia and falls-related long-term mortality risk in the elderly. , 2012, Journal of the American Medical Directors Association.

[20]  J. Nørgaard,et al.  Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia. , 2011, The Journal of urology.

[21]  T. Tammela,et al.  Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. , 2010, European urology.

[22]  Poul Jennum,et al.  The standardisation of terminology in nocturia: Report from the standardisation sub‐committee of the International Continence Society , 2002, Neurourology and urodynamics.

[23]  Xiaohong Yan,et al.  OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. , 2013, The Journal of urology.

[24]  P. Abrams.  Reviewing the ICS 2002 terminology report: The ongoing debate , 2006, Neurourology and urodynamics.

[25]  V. Nitti,et al.  Degree of bother caused by nocturia in women , 2004, Neurourology and urodynamics.